144222-22-0

Basic information

• Product Name: 1-Boc-4-(aminomethyl)piperidine
• Synonyms: 1-Boc-4-(aminomethyl)piperidine, 1-Boc-4-piperidylmethylamine;4-(aminometh;t-Butyl 4-(aminomethyl)piperidine-1-carboxylate;1-Boc-4-(aminomethyl)piperidine ,97%;4-(Aminomethyl)piperidine, N1-BOC protected 97%;1-Boc-4-aminomethylpiperi...;4-(Aminomethyl)-1-(tert-butoxycarbonyl)piperidine, tert-Butyl 4-(aminomethyl)piperidine-1-carboxylate;1,1-DiMethylethyl 4-(aMinoMethyl)-1-piperidinecarboxylate
• CAS NO: 144222-22-0
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: pharmacetical;Piperidine;Heterocyclic Compounds;Building Blocks;Heterocyclic Building Blocks;Piperidines
• Mol File: 144222-22-0.mol
• Article Data: 42

Chemical Properties

• Boiling Point: 237-238 °C(lit.)
• Flash Point: >230 °F
• Appearance: Colorless to yellow/Liquid or Low Melting Solid
• Density: 1.013 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00325mmHg at 25°C
• Refractive Index: n20/D 1.473(lit.)
• Storage Temp.: Room temperature.
• Solubility: Soluble in chloroform and methanol.
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: 1-Boc-4-(aminomethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(aminomethyl)piperidine(144222-22-0)
• EPA Substance Registry System: 1-Boc-4-(aminomethyl)piperidine(144222-22-0)

Safety Data

• Hazard Codes: Xi,C,N
• Statements: 36/37/38-34-50
• Safety Statements: 26-36-45-36/37/39-24/25-23-61
• RIDADR: UN 3082 9 / PGIII
• WGK Germany: 3
• F: 10-34
• HazardClass: IRRITANT
• Hazardous Substances Data: 144222-22-0(Hazardous Substances Data)

Usage

Chemical Properties

White Low Melting Solid

Uses

Different sources of media describe the Uses of 144222-22-0 differently. You can refer to the following data:
1. 1-Boc-4-(aminomethyl)piperidine is a protected 4-substituted piperidinecarboxylate used in the preparation of orally active platelet-activating factor antagonists as well as other biologically active compounds.
2. 4-Aminomethyl-1-Boc-piperidine is used in the preparation biologically active compounds and orally active platelet-activating factor antagonists. It is used as an inhibitor for aspartic acid protease and Kinesin spindle protein. It is an active reactant involved in the enantioselective synthesis of N-alkyl terminal aziridines.

InChI:InChI=1/C11H22N2O2/c1-10(2,3)15-9(14)13-7-5-11(4,12)6-8-13/h5-8,12H2,1-4H3

Upstream product

• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 7144-05-0 4-Aminomethylpiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 138022-91-0 tert-butyl 4-(methoxymethylene)piperidine-1-carboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 6457-49-4 4-piperidinemethanol 
• 1038352-48-5 (E)-tert-butyl 4-[(hydroxyimino)(pyridin-3-yl)methyl]-piperidine-1-carboxylate 
• 77-92-9 citric acid 
• 7646-93-7 potassium hydrogensulfate 
• 153747-01-4 4-(phthalimidomethyl)piperidine 
• 161975-39-9 tert-butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 498-94-2 isonipecotic acid 

Downstream Products

• 188973-04-8 N-tert-butyloxycarbonyl-4-(4-amino-5-chloro-2-methoxyphenylcarbonylaminomethyl)piperidine 
• 913548-57-9 2-{4-[(3-Adamantan-1-yl-ureido)-methyl]-piperidine-1-carbonyl}-benzoic acid methyl ester 
• 913548-58-0 3-{4-[(3-adamantan-1-yl-ureido)-methyl]-piperidine-1-carbonyl}-benzoic acid methyl ester 
• 913548-59-1 4-{4-[(3-Adamantan-1-yl-ureido)-methyl]-piperidine-1-carbonyl}-benzoic acid methyl ester 
• 600725-25-5 4-[(2-aminophenylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 
• 616224-23-8 2-[(1-tert-butoxycarbonyl-piperidin-4-ylmethyl)-amino]-1H-benzimidazole-5-carboxylic acid ethyl ester 
• 616224-95-4 1-Boc-4-(2-aminobenzylthioureamethyl)piperidine 
• 881833-19-8 4-(N-(2-methyl-3-phenyl-2-(E)-propenyl)aminomethyl)-1-t-butoxycarbonylpiperidine 
• 226249-70-3 4-[{(N-(benzyloxycarbonyl)glycyl)amino}methyl]-1-(tert-butoxycarbonyl)piperidine 
• 301226-37-9 4-(N-((4-fluorophenyl)sulfonyl)aminomethyl)-1-tert-butoxycarbonylpiperidine 

Relevant articles and documents

Efficient and scalable method for the selective alkylation and acylation of secondary amines in the presence of primary amines

Selective substitution of secondary amines in the presence of primary amines is performed by using the reaction solvent, methyl isobutylketone (MIBK), as a temporary protecting group for the primary amine. After acylation or alkylation of the secondary amine, the resulting imine intermediate is smoothly hydrolysed, leading to the free primary amine in high yield and purity. This procedure represents a cheap and scalable alternative to multistep methods requiring several protections and deprotections.

Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues

Therapies addressing multiple stages of Plasmodium falciparum life cycle are highly desirable for implementing malaria elimination strategies. MMV019918 (1, 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine) was selected from the MMV Malaria Box for its dual activity against both asexual stages and gametocytes. In-depth structure-activity relationship studies and cytotoxicity evaluation led to the selection of 25 for further biological investigation. The potential transmission blocking activity of 25 versus P. falciparum was confirmed through the standard membrane-feeding assay. Both 1 and 25 significantly prolonged atrioventricular conduction time in Langendorff-isolated rat hearts, and showed inhibitory activity of Ba2+ current through Cav1.2 channels. An in silico target-fishing study suggested the enzyme phosphoethanolamine methyltransferase (PfPMT) as a potential target. However, compound activity against PfPMT did not track with the antiplasmodial activity, suggesting the latter activity relies on a different molecular target. Nevertheless, 25 showed interesting activity against PfPMT, which could be an important starting point for the identification of more potent inhibitors active against both sexual and asexual stages of the parasite.

N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditio